Richard Sposto




Ph.D.(哲学、生物統計学) カルフォルニア大学(米国カリフォルニア州ロサンゼルス)
M.S. (生物統計学) カルフォルニア大学(米国カリフォルニア州ロサンゼルス)
B.A. (数学)カルフォルニア大学(米国カリフォルニア州ロサンゼルス)


  • 2019-現在統計部部長 主任研究員
  • 1988-1992年統計部 研究員
  • 2019-現在

    名誉教授 ケック医学校予防医学部

  • 2005-2019年

    教授 ケック医学校予防医学部・小児科学

  • 1994-2005年

    准教授 ケック医学校予防医学部

  • 1981-1988年

    助教 ケック医学校予防医学部

  • 2004-2019年

    生物統計学・生物情報科学ディレクター ロサンゼルス小児病院 血液/腫瘍/BMT科

  • 2002-2004年

    統計学者 小児腫瘍グループ

  • 1994-2002年

    生物統計学者 小児がん/小児腫瘍グループ

  • 1981-1988年

    生物統計学者 小児がん研究グループ

  • 1992-1994年統計学者 Co-PIエイズワクチン調査グループ


  1. Nakamura, N., R. Sposto, R.C. Miller, T. Hiraoka, and N. Takeichi, X-ray-induced mutations in cultured human thyroid cells. Radiation Research, 1989. 119(1): p. 123-33.
  2. Nakamura, N., R. Sposto, J. Kushiro, and M. Akiyama, Is interindividual variation of cellular radiosensitivity real or artifactual? Radiation Research, 1991. 125(3): p. 326-30.
  3. Preston, R. and R. Sposto, RBE and dose-response functions. Is it necessary to introduce the concept of relative biological effectiveness? RERF Update, 1991. August.
  4. Sposto, R., D.O. Stram, and A.A. Awa, An estimate of the magnitude of random errors in the DS86 dosimetry from data on chromosome aberrations and severe epilation. Radiation Research, 1991. 128(2): p. 157-69.
  5. Stram, D.O. and R. Sposto, Recent uses of biological data for the evaluation of A-bomb radiation dosimetry. Journal of Radiation Research, 1991. 32(Suppl): p. 122-35.
  6. Fujiwara, S., M. Shiraki, R. Sposto, K. Kodama, H. Sasaki, Y. Hosoda, and K. Shimaoka, Parathyroid-Hormone, Calcitonin, and Osteocalcin Levels among Japanese – Population Based Study. Journal of Bone and Mineral Research, 1992. 7: p. S243-S243.
  7. Fujiwara, S., R. Sposto, H. Ezaki, S. Akiba, K. Neriishi, K. Kodama, Y. Hosoda, and K. Shimaoka, Hyperparathyroidism among atomic bomb survivors in Hiroshima. Radiation Research, 1992. 130(3): p. 372-8.
  8. Sposto, R., D.L. Preston, Y. Shimizu, and K. Mabuchi, The effect of diagnostic misclassification on non-cancer and cancer mortality dose response in A-bomb survivors. Biometrics, 1992. 48(2): p. 605-17.
  9. Sposto, R., H.N. Sather, and S.A. Baker, A comparison of tests of the difference in the proportion of patients who are cured. Biometrics, 1992. 48(1): p. 87-99.
  10. Nakamura, N., R. Sposto, and M. Akiyama, Dose survival of G0 lymphocytes irradiated in vitro: a test for a possible population bias in the cohort of atomic bomb survivors exposed to high doses. Radiation Research, 1993. 134(3): p. 316-22.
  11. Stram, D.O., R. Sposto, D. Preston, S. Abrahamson, T. Honda, and A.A. Awa, Stable chromosome aberrations among A-bomb survivors: an update. Radiation Research, 1993. 136(1): p. 29-36.
  12. Fujiwara, S., R. Sposto, M. Shiraki, N. Yokoyama, H. Sasaki, K. Kodama, and K. Shimaoka, Levels of parathyroid hormone and calcitonin in serum among atomic bomb survivors. Radiation Research, 1994. 137(1): p. 96-103.
  13. Ohtaki, K., R. Sposto, Y. Kodama, M. Nakano, and A.A. Awa, Aneuploidy in somatic cells of in utero exposed A-bomb survivors in Hiroshima. Mutation Research, 1994. 316(1): p. 49-58.
  14. Sposto, R., D. Stablein, and S. Carter-Campbell, A partially grouped logrank test. Statistics in Medicine, 1997. 16(6): p. 695-704.
  15. Sposto, R. and D.O. Stram, A strategic view of randomized trial design in low-incidence paediatric cancer. Statistics in Medicine, 1999. 18(10): p. 1183-97.
  16. Nachman, J., R. Sposto, P. Herzog, J. Cich, C. Fryer, R. Hutchinson, M.E. Kadin, and K. White, Randomized comparison of low-dose involved field radiation and no radiation for children with Hodgkin’s disease who achieve a complete response to chemotherapy. Journal of Clinical Oncology, 2002. 20(18): p. 3765-3771.
  17. Sposto, R., Cure model analysis in cancer: An application to data from the Children’s Cancer Group. Statistics in Medicine, 2002. 21: p. 293-312.
  18. Sposto, R., W.B. London, and T.A. Alonzo, Criteria for optimizing prognostic risk groups in pediatric cancer: analysis of data from the Children’s Oncology Group. Journal of Clinical Oncology, 2007. 25(15): p. 2070-7.
  19. Sposto, R. and P.S. Gaynon, An adjustment for patient heterogeneity in the design of two-stage phase II trials. Statistics in Medicine, 2009. 28(20): p. 2566 – 2579.
  20. Sposto, R. and S. Groshen, A wide-spectrum paired comparison of the properties of the Rolling 6 and 3+3 Phase I study designs. Contemp Clin Trials, 2011. 32(5): p. 694-703.
  21. Sposto, R., T.H.M. Keegan, C. Vigen, M.L. Kwan, L. Bernstein, E.M. John, I. Cheng, J. Yang, J. Koo, A.W. Kurian, B.J. Caan, Y.N. Lu, K.R. Monroe, S. Shariff-Marco, S.L. Gomez, and A.H. Wu, The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality. Cancer Epidemiology Biomarkers & Prevention, 2016. 25(7): p. 1064-1072.
  22. Marachelian, A., J.G. Villablanca, C.W. Liu, B. Liu, F. Goodarzian, H.A. Lai, H. Shimada, H.C. Tran, J.A. Parra, R. Gallego, N. Bedrossian, S. Young, S. Czarnecki, R. Kennedy, B.D. Weiss, K. Goldsmith, M. Granger, K.K. Matthay, S. Groshen, S. Asgharzadeh, R. Sposto, and R.C. Seeger, Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clin Cancer Res, 2017. 23(18): p. 5374-5383.
  23. Maruffi, M., R. Sposto, M.J. Oberley, L. Kysh, and E. Orgel, Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. Leukemia, 2018. 32(7): p. 1515-1528.
  24. Bhojwani, D., R. Sposto, N.N. Shah, V. Rodriguez, C. Yuan, M. Stetler-Stevenson, M.M. O’Brien, J.L. McNeer, A. Quereshi, A. Cabannes, P. Schlegel, C. Rossig, L. Dalla-Pozza, K. August, S. Alexander, J.P. Bourquin, M. Zwaan, E.A. Raetz, M.L. Loh, and S.R. Rheingold, Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia, 2019. 33(4): p. 884-892.
  25. Ji, L., J.P. Lewinger, M. Krailo, S. Groshen, D.V. Conti, S. Asgharzadeh, and R. Sposto, Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method. Pharm Stat, 2019. 18(6): p. 659-670.
  26. Ji, L., L.M. McShane, M. Krailo, and R. Sposto, Bias in retrospective analyses of biomarker effect using data from an outcome-adaptive randomized trial. Clin Trials, 2019. 16(6): p. 599-609.